Cagrilintide + Semaglutide

Why people combine them

An investigational amylin analogue combined with an approved GLP-1 receptor agonist in a sponsor's Phase 3 programme for weight management — the rare pairing where the combination itself is genuinely under study.

Evidence for the combination

REDEFINE 1 (Phase 3, registered) evaluates cagrilintide with semaglutide versus semaglutide alone in weight management; REDEFINE 2 covers a type 2 diabetes population. Registration is not approval, and topline disclosures are not a label. ClinicalTrials.gov — REDEFINE 1 (NCT05567796)

Evidence for each component

• Semaglutide — Approved drug substance with an extensive labelled and trial evidence base (STEP, SUSTAIN programmes).
• Cagrilintide — Investigational; no approved product. ClinicalTrials.gov listed 44 registered studies with cagrilintide as an intervention at the identity record's review.

Commonly reported dosing and protocols

Displayed source by source. Therapept does not compose these into a recommended protocol.

• OFFICIALRegistered trial protocols (ClinicalTrials.gov)

  Co-formulated/fixed-ratio co-administration at sponsor-specified dose levels, per the registered protocol. Exact dose arms are stated on the registry record, not paraphrased here.

  Investigational product under clinical-trial conditions with eligibility criteria and monitoring — categorically different from self-administration.

  Checked 17 September 2026 · ClinicalTrials.gov — REDEFINE 1 (NCT05567796)

Potential overlap and concerns

• Cagrilintide has no approved product; the combination is not an approved therapy anywhere in the United States.
• Trial conditions (eligibility, monitoring, product quality) do not transfer to non-trial settings.